SDGR — Schrodinger, Inc.
—
Nasdaq ·
Health Care ·
Pharmaceuticals ·
CIK 1490978 ·
Last close
$25.66
Market Cap
$1.68B
52W High
$34.00
52W Low
$10.94
ADV30
1,846,638
Next earnings
2026-11-04
Quarterly Fundamentals
Revenues vs Net Income (last 4 Q)
Assets vs Liabilities (last 4 Q)
| Period | Revenues | Gross profit | Op income | Net income | Assets | Cash | Liabilities |
|---|---|---|---|---|---|---|---|
| Sep 2026 | 64,491,000 | 38,253,000 | -26,129,000 | -37,711,000 | 611,940,000 | 246,983,000 | 310,110,000 |
| Jun 2026 | 58,889,000 | 32,432,000 | -41,547,000 | 5,975,000 | 640,394,000 | 287,853,000 | 311,438,000 |
| Mar 2026 | 58,587,000 | 29,547,000 | -48,794,000 | -60,026,000 | 634,187,000 | 260,255,000 | 320,639,000 |
| Dec 2025 | 87,235,000 | 57,293,000 | -17,157,000 | 32,511,000 | 726,160,000 | 230,517,000 | 362,107,000 |
Cashflow TTM (yfinance, fills SEC gap)
Operating CF
$-112,575,000
Investing CF
$180,567,000
Financing CF
$4,138,000
CapEx
$-4,199,000
Dividends Paid
—
Buybacks
—
EPS Diluted TTM
$-1.68
As of
2026-11-08
Balance + Analyst (yfinance extras)
Retained Earnings
$-720,568,000
Inventory
—
Receivables
$70,835,000
ST Investments
$119,375,000
EBIT TTM
$-133,627,000
Pretax Income TTM
$-56,853,000
Interest Exp TTM
—
Analysts
7
Yahoo Snapshot (yfinance, live)
Total Revenue
$269,201,984
EBITDA
$-127,765,000
Free Cash Flow
$-32,955,876
Enterprise Value
$1,977,088,768
Total Cash
$366,358,016
Total Debt
$104,627,000
Shares Out
65,641,435
Trailing EPS
$-0.79
Book Value
$4.02
ROE
-19.0%
ROA
-13.2%
Div Yield
0.00%
Annual Trend (SEC EDGAR, last 4y)
Revenues vs Net Income (last 4y)
| FY end | Revenues | Op income | Net income | Assets | Liabilities | Equity | Op cash flow |
|---|---|---|---|---|---|---|---|
| Dec 2025 | 255,869,000 | -166,896,000 | -103,265,000 | 726,160,000 | 362,107,000 | 364,053,000 | 13,899,000 |
| Dec 2024 | 207,539,000 | -209,296,000 | -187,123,000 | 823,226,000 | 401,781,000 | 421,445,000 | -157,368,000 |
| Dec 2023 | 216,666,000 | -177,448,000 | 40,720,000 | 802,955,000 | 254,397,000 | 548,558,000 | -136,733,000 |
| Dec 2022 | 180,955,000 | -146,817,000 | -149,186,000 | 688,587,000 | 240,682,000 | 447,894,000 | -119,683,000 |
TTM Snapshot
Revenues TTM
$259,035,000
NetIncome TTM
$-54,335,000
OpCashFlow TTM
—
Assets (Latest)
$640,394,000
Forward EPS
$-1.35
Max Pain — expiry 2026-12-18
max pain strike: $30.00 · spot: $27.20 · call oi: 7,822 · put oi: 6,804
Expected Move to 2026-12-18:
±$5.67
(20.86%) —
implied range
$21.52 –
$32.88
· ATM straddle on $27.50 strike
Peers — same industry
| Ticker | Name | Market Cap | Last | Daily % |
|---|---|---|---|---|
| BRVE | Braveheart Bio, Inc. | $1.69B | $18.78 | — |
| SUPN | Supernus, Inc. | $1.69B | $29.04 | — |
| RARE | Ultragenyx Pharmaceutical Inc. | $1.70B | $16.70 | — |
| STOK | Stoke Therapeutics, Inc. | $1.73B | $26.41 | — |
| ZYME | Zymeworks Inc. | $1.78B | $25.84 | — |
News headlines (Yahoo Finance, 1h cache)
Schrodinger Eyes Growth From AI Assistant Bunsen and Hosted Software Shift
2026-11-13 22:14 · Yahoo
Schrödinger, Inc. Q3 2026 Earnings Call Summary
2026-11-05 13:30 · Yahoo
What Schrodinger (SDGR) Said on Its Q3 Earnings Call
2026-11-05 04:14 · Yahoo
Schrodinger, Inc. (SDGR) Reports Q3 Loss, Beats Revenue Estimates
2026-11-04 23:45 · Yahoo
Schrödinger Reports Third Quarter 2026 Financial Results
2026-11-04 21:05 · Yahoo
Earnings Preview: Schrodinger, Inc. (SDGR) Q3 Earnings Expected to Decline
2026-10-28 13:00 · Yahoo
Schrödinger to Present at UBS Global Healthcare Conference
2026-10-28 12:30 · Yahoo
Schrödinger Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
2026-10-26 12:30 · Yahoo
Schrödinger to Announce Third Quarter 2026 Financial Results on November 4
2026-10-21 12:30 · Yahoo
Schrödinger Research Published in Nature Reveals New Insights into Lithium-Ion Battery Chemistry
2026-10-14 15:05 · Yahoo
Recent Insider Activity
No insider activity indexed for this ticker.